文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症重症综合管理与镇静镇痛

养老院居住者COVID-19口服抗病毒治疗后的临床结局

Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论养老院COVID-19患者使用莫诺拉韦或奈玛特韦/利托那韦与住院及病情进展风险降低相关(回顾性队列)。

这项全地区回顾性队列研究纳入2022年2月16日至3月31日香港养老院COVID-19患者14617例,比较莫诺拉韦、奈玛特韦/利托那韦与未用口服抗病毒药的结局。中位随访30天,42.6%住院、15.8%出现住院期间病情进展。倾向评分加权后,两种药物均与住院风险降低(莫诺拉韦wHR 0.46,95%CI 0.37-0.57;奈玛特韦/利托那韦wHR 0.46,95%CI 0.32-0.65)和病情进展风险降低(wHR 0.35,95%CI 0.23-0.51;wHR 0.17,95%CI 0.06-0.44)相关。两种药物直接比较时结局相当。

要点

  • 养老院COVID-19患者中,莫诺拉韦与住院风险降低相关(wHR 0.46,95%CI 0.37-0.57,P<.001)。
  • 奈玛特韦/利托那韦与住院风险降低相关(wHR 0.46,95%CI 0.32-0.65,P<.001)。
  • 莫诺拉韦与住院期间病情进展风险降低相关(wHR 0.35,95%CI 0.23-0.51,P<.001)。
  • 奈玛特韦/利托那韦与住院期间病情进展风险降低相关(wHR 0.17,95%CI 0.06-0.44,P<.001)。
  • 两种药物直接比较:住院wHR 1.00(95%CI 0.75-1.33,P=.99),病情进展wHR 0.49(95%CI 0.20-1.20,P=.12),结局相当。

适用人群与场景

  • 香港养老院居住的COVID-19患者,非住院老年人群(平均[SD]年龄84.8[10.2]岁;女性8222例[56.2%])。
  • 研究期间为2022年2月16日至3月31日,末次随访2022年4月25日。

处置流程与药物剂量

  • 暴露分组:莫诺拉韦5195例(35.5%)、奈玛特韦/利托那韦483例(3.3%)、未用口服抗病毒药8939例(61.2%)。

研究设计与关键结果

  • 研究类型:全地区回顾性队列研究,纳入14617例养老院COVID-19患者。
  • 主要终点住院:6223例(42.6%)住院;中位随访30天(IQR 30-30天)。
  • 次要终点住院期间病情进展(入住ICU、有创机械通气和/或死亡):2307例(15.8%)。
  • 倾向评分加权后,莫诺拉韦 vs 未用口服抗病毒药:住院wHR 0.46(95%CI 0.37-0.57;P<.001),病情进展wHR 0.35(95%CI 0.23-0.51;P<.001)。
  • 奈玛特韦/利托那韦 vs 未用口服抗病毒药:住院wHR 0.46(95%CI 0.32-0.65;P<.001),病情进展wHR 0.17(95%CI 0.06-0.44;P<.001)。
  • 奈玛特韦/利托那韦 vs 莫诺拉韦:住院wHR 1.00(95%CI 0.75-1.33;P=.99),病情进展wHR 0.49(95%CI 0.20-1.20;P=.12),两者结局相当。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,养老院居住者使用口服抗病毒药治疗COVID-19与住院和住院期间病情进展风险降低相关。
  • 作者认为,该养老院人群的研究结果可合理外推至社区其他衰弱老年患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Older patients living in nursing homes are at very high risk of mortality after getting COVID-19.

OBJECTIVE: To evaluate outcomes following oral antiviral treatment for COVID-19 among nonhospitalized older patients living in nursing homes.

DESIGN, SETTING, AND PARTICIPANTS: This is a territory-wide, retrospective cohort study conducted between February 16 and March 31, 2022, with the last follow-up date on April 25, 2022. Participants were patients with COVID-19 living in nursing homes in Hong Kong. Data analysis was performed from May to June 2022.

EXPOSURES: Molnupiravir, nirmatrelvir/ritonavir, or no oral antiviral treatment.

MAIN OUTCOMES AND MEASURES: The primary outcome was hospitalization for COVID-19, and the secondary outcome was risk of inpatient disease progression (ie, admission to intensive care unit, use of invasive mechanical ventilation, and/or death).

RESULTS: Of 14 617 patients (mean [SD] age, 84.8 [10.2] years; 8222 women [56.2%]), 8939 (61.2%) did not use oral antivirals, 5195 (35.5%) used molnupiravir, and 483 (3.3%) used nirmatrelvir/ritonavir. Compared with patients who did not use oral antivirals, those who used molnupiravir and nirmatrelvir/ritonavir were more likely to be female and less likely to have comorbid illnesses and hospitalization in the past year. At a median (IQR) follow-up of 30 (30-30) days, 6223 patients (42.6%) were hospitalized and 2307 patients (15.8%) experienced inpatient disease progression. After propensity score weighting, both molnupiravir and nirmatrelvir/ritonavir were associated with a reduced risk of hospitalization (molnupiravir, weighted hazard ratio [wHR], 0.46; 95% CI, 0.37-0.57; P < .001; nirmatrelvir/ritonavir, wHR, 0.46; 95% CI, 0.32-0.65; P < .001) and inpatient disease progression (molnupiravir, wHR, 0.35; 95% CI, 0.23-0.51; P < .001; nirmatrelvir/ritonavir, wHR, 0.17; 95% CI, 0.06-0.44; P < .001). Nirmatrelvir/ritonavir was comparable to molnupiravir in achieving better clinical outcomes (hospitalization, wHR, 1.00; 95% CI, 0.75-1.33; P = .99; inpatient disease progression, wHR, 0.49; 95% CI, 0.20-1.20; P = .12).

CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, the use of oral antivirals to treat COVID-19 was associated with a reduced risk of hospitalization and inpatient disease progression among patients living in nursing homes. The findings of this study of nursing home residents could be reasonably extrapolated to other frail older patients living in the community.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Ma BH, Yip TC, Lui GC, et al. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes. JAMA Netw Open. 2023. PMID: 37103932. doi:10.1001/jamanetworkopen.2023.10887

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。